GlassScriptPhysician profile
Kimberly Barnes
NPI 1649634577
$8,629.29
in general payments reported to CMS, 2019-2025
35 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,441 · 2022: $1,868 · 2023: $2,066 · 2024: $1,834 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,300 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,300.43 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,339.83 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $923.68 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $790.64 | 2021-2025 | |
| Lilly USA, LLC | $622.98 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $508.05 | 2021-2025 | Xifaxan, Trulance |
| Pfizer INC. | $497.71 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $495.75 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $444.81 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $406.75 | 2021-2025 | Veozah, Myrbetriq |
| Amgen INC. | $256.64 | 2021-2025 | Otezla, Repatha, Evenity |
| Sanofi-Aventis U.S. LLC | $254.26 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $247.57 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $242.93 | 2021-2023 | Seglentis, Livalo |
| Abbott Laboratories | $235.15 | 2021-2024 | Freestyle Libre, Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $214.78 | 2021-2024 | Belsomra, Steglatro, Steglujan |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $164.36 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $161.13 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $145.53 | 2022 | |
| Janssen Pharmaceuticals, INC | $138.73 | 2021-2024 | Xarelto, Spravato |
| Novartis Pharmaceuticals Corporation | $89.18 | 2021-2023 | |
| Amarin Pharma, INC. | $81.79 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $43.14 | 2022-2023 | |
| Eisai INC. | $40.35 | 2021 | |
| Phathom Pharmaceuticals, INC. | $40.04 | 2024-2025 | Voquezna |
| Dynavax Technologies Corporation | $36.81 | 2024-2025 | Heplisav-B |
| Corcept Therapeutics | $34.89 | 2024 | Korlym |
| Soleno Therapeutics, INC. | $33.34 | 2025 | Vykat Xr |
| Genentech USA, INC. | $26.09 | 2021-2022 | |
| Axsome Therapeutics, INC. | $20.10 | 2025 | Symbravo |
| Seqirus USA INC | $19.25 | 2025 | Flucelvax, Fluad |
| Sumitomo Pharma America, INC. | $18.11 | 2024 | Gemtesa |
| Arbor Pharmaceuticals, INC. | $15.45 | 2021 | |
| Dexcom, INC. | $14.77 | 2021 | |
| Althera Pharmaceuticals LLC | $13.57 | 2021 | |
| Adlon Therapeutics L.P. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.